Adding life to medicines

Using AI and advanced analytics, we perfect proven medicines through Repurposing & Reformulation programs

Get in touch
Learn more
Our Mission

Uncover New Possibilities for Approved Drugs

Revio’s mission is to pivot approved medicines towards new indications or optimize its use within existing indications.

Our approach creates opportunities to leverage novel biology to explore new indications, innovate dosage forms, delivery systems, and new routes of administration.

We aim to accelerate drug development, reduce risk of failures, and deliver better outcomes for patients while creating meaningful value for all stakeholders.

Partner with us
Who We Are

A specialty pharma company with end-to-end product development expertise

A century of collective experience in pharma R&D, finance, and AI domains. With proven success in regulatory approvals, global & regional licensing deals, and new product launches across therapeutic areas, we know how to make a molecule market-ready.

Learn more
What We Do

Blending high-reward repurposing with low-risk reformulations

We reimagine approved drugs to create lower-risk and faster-to-market products at scale.

Approved drugs have an established safety record.
‍
We seek to uncover new possibilities for approved drugs, which can lead to more efficient drug development, positively impacting all stakeholders.

John Carter Avatar Circle Image - Laboratory X Webflow Template
John Carter
Principal scientist
Learn more
Get in touch
Learn more
Revio develops drugs for rare diseases.

Drug development is expensive, risky, and time-consuming.

New drug candidates often fail in early-stage clinical trials due to safety concerns. 
Approved drugs have an established track record of safety.

Our Strengths
Our Business Model

We believe strong partnerships & efficient structuring are critical to resolving the complexity of drug development. Through early-stage collaboration and late-stage licensing, our Hub-and-spoke model enables focus on individual assets for streamlined development.

Learn more
Rare Indications

Why Rare Diseases?

These conditions may affect fewer people, but their impact is profound.

By focusing on rare diseases and niche therapeutic areas, we dedicate our expertise to creating breakthrough solutions for patients who need them most.

Learn more
01

Unmet Needs

With over 7,000 known rare diseases, 95% lack FDA-approved treatments. We aim to close this gap.

02

Smarter Development

Rare disease research benefits from regulatory incentives and the voices of empowered patient communities.

Therapeutics Areas

Our Therapeutics Areas 

We seek to uncover new possibilities for approved drugs, specifically in rare diseases & niche indications.

Muscular Dystrophy

Collaborating on an approved DMD molecule using AI-enabled approaches to explore potential applications across multiple dystrophinopathies.

Glioblastoma

Partnering with nanotechnology experts, we’re developing an innovative intra-tumoral formulation to enhance efficacy while minimizing side effects.

Other Assets & Indications

Exploring treatments for neurological diseases and antimicrobial resistance (AMR).

Learn more

Therapeutics Areas

High cellular toxicity is a common problem with oncology drugs. In partnership with a major pharma company, Revio is co-developing a new drug combination with lower cytotoxicity and novel route of delivery for glioblastoma. 

Muscular Dystrophy

Muscle weakness and loss of muscle mass are typical symptoms of muscular dystrophy. The root cause of the condition is genetic and has no approved medications.

Revio is working with a startup with expertise in artificial intelligence and developing a new application for a drug that is approved for the management of diabetes.

Glioblastoma

High cellular toxicity is a common problem with oncology drugs. In partnership with a major pharma company, Revio is co-developing a new drug combination with lower cytotoxicity and novel route of delivery for glioblastoma. 

Learn more
News and Media

News and Media

Browse all articles
Nanoform Partners With Revio Therapeutics To Develop Long-Acting Locally-Delivered Hydrogel Nanoformulation To Treat Glioma

Nanoform Partners With Revio Therapeutics To Develop Long-Acting Locally-Delivered Hydrogel Nanoformulation To Treat Glioma

Revio Therapeutics, a privately held specialty pharma start-up focused on repurposing & optimizing approved medicines...

October 27, 2025
News and Media
Learn more
Revio Therapeutics Announces Licensing Agreement with Peptris Technologies & Poster Presentation at the 2025 Muscular Dystrophy Association Conference

Revio Therapeutics Announces Licensing Agreement with Peptris Technologies & Poster Presentation at the 2025 Muscular Dystrophy Association Conference

Revio Therapeutics, a privately held specialty pharma start-up focused on repurposing & optimizing approved medicines...

October 27, 2025
News and Media
Learn more

Partner With Us

At Revio we have the passion & expertise to develop successful drugs that improve patients’ lives & create value for all stakeholders. And we value partnerships that are mutually accretive and help us succeed in our mission.

Talk to Us

For Researchers

Have an idea or IP ready for development? Partner with us to turn it into a reality.

Get in touch

For Pharmaceutical and Biotech Companies

Let’s join forces to bring cutting-edge programs to the finish line.

Get in touch

For Investors

Be part of our mission to revolutionize drug development and deliver measurable impact.

Get in touch